Sacubitril/valsartan and circulating neprilysin hypothesis in patients with HFpEF

被引：0
|
作者：
Santiago-Vacas, E. [1 ]
Codina, P. [1 ]
Domingo, M. [1 ]
De Antonio, M. [1 ]
Zamora, E. [1 ]
Santesmases, J. [1 ]
Julian, M. T. [1 ]
Diez-Quevedo, C. [1 ]
Troya, M., I [1 ]
Boldo, M. [1 ]
Altimir, S. [1 ]
Nunez, J. [2 ]
Gonzalez, B. [1 ]
Lupon, J. [1 ]
Bayes-Genis, A. [1 ]
机构：
[1] Germans Trias & Pujol Hosp, Badalona, Spain
[2] Univ Gen Hosp Valencia, Valencia, Spain
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：860 / 860
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan
    Chrysant, Steven G.
    JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2017, 11 (07) : 461 - 468
  • [22] Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan
    Clements, Richard T.
    Vang, Alexander
    Fernandez-Nicolas, Ana
    Kue, Nouaying R.
    Mancini, Thomas J.
    Morrison, Alan R.
    Mallem, Krishna
    McCullough, Danielle J.
    Choudhary, Gaurav
    CIRCULATION-HEART FAILURE, 2019, 12 (11)
  • [23] Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck
    Ansara, A. J.
    Kolanczyk, D. M.
    Koehler, J. M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (02) : 119 - 127
  • [24] Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF
    Schauer, Antje
    Adams, Volker
    Augstein, Antje
    Jannasch, Anett
    Draskowski, Runa
    Kirchhoff, Virginia
    Goto, Keita
    Mittag, Jeniffer
    Galli, Roberta
    Maennel, Anita
    Barthel, Peggy
    Linke, Axel
    Winzer, Ephraim B.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (07)
  • [25] Meet Me in the Middle Lessons From the Cardiorenal Advisory Committee for Sacubitril/Valsartan in HFpEF
    O'Connor, Christopher M.
    JACC-HEART FAILURE, 2021, 9 (02) : 161 - 163
  • [26] Sacubitril/Valsartan Therapy for AF and HFpEF br Is the Glass Half Empty or Half Full?
    Piccini, Jonathan P.
    JACC-HEART FAILURE, 2022, 10 (05) : 347 - 349
  • [27] EFFECTS OF SACUBITRIL/VALSARTAN OR VALSARTAN IN DE NOVO VS. CHRONIC HFPEF AND HFMREF: THE PARAGLIDE-HF TRIAL
    Murray, Evan
    Cyr, Derek D.
    Morrow, David A.
    Starling, Randall C.
    Zieroth, Shelley R.
    Hernandez, Adrian F.
    Williamson, Kristin
    Lepage, Serge
    Fudim, Marat
    Desai, Akshay S.
    Ward, Jonathan
    Solomon, Scott D.
    Mentz, Robert John
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 4607 - 4607
  • [28] The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients
    Stinkens, R.
    van der Kolk, B. W.
    Jordan, J.
    Jax, T.
    Engeli, S.
    Heise, T.
    Jocken, J. W.
    May, M.
    Schindler, C.
    Havekes, B.
    Schaper, N.
    Albrecht, D.
    Kaiser, S.
    Hartmann, N.
    Letzkus, M.
    Langenickel, T. H.
    Goossens, G. H.
    Blaak, E. E.
    SCIENTIFIC REPORTS, 2018, 8
  • [29] Sacubitril/valsartan
    不详
    AUSTRALIAN PRESCRIBER, 2016, 39 (06) : 226 - 227
  • [30] The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients
    R. Stinkens
    B. W. van der Kolk
    J. Jordan
    T. Jax
    S. Engeli
    T. Heise
    J. W. Jocken
    M. May
    C. Schindler
    B. Havekes
    N. Schaper
    D. Albrecht
    S. Kaiser
    N. Hartmann
    M. Letzkus
    T. H. Langenickel
    G. H. Goossens
    E. E. Blaak
    Scientific Reports, 8
12345